Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Long-Term Debt Repayments Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In Process Receivables - Net Shares Issued Shares Outstanding Shares Outstanding

Tandem Diabetes Care (TNDM) Shares Repurchased (2024)

Tandem Diabetes Care filings provide 1 years of Shares Repurchased readings, the most recent being $30.0 million for Q1 2024.

On a quarterly basis, Shares Repurchased changed N/A to $30.0 million in Q1 2024 year-over-year; TTM through Dec 2024 was $30.0 million, a N/A change, with the full-year FY2024 number at $30.0 million, changed N/A from a year prior.
Shares Repurchased hit $30.0 million in Q1 2024 for Tandem Diabetes Care.
In the past five years, Shares Repurchased ranged from a high of $30.0 million in Q1 2024 to a low of $30.0 million in Q1 2024.